Transgene Appoints Renowned Pharmaceutical Executive Emmanuelle Quilès to Board of Directors

Transgene, a biotechnology company specializing in cancer immunotherapies, appoints Emmanuelle Quilès as an independent director to its Board. Quilès, with over 25 years of experience in global pharmaceutical leadership, succeeds Philippe Archinard. The appointment is effective from July 9, 2025, until the 2026 Annual General Meeting. Transgene’s CEO, Dr. Alessandro Riva, acknowledges Archinard’s contributions and welcomes Quilès’ expertise to enhance the company’s mission of improving patient lives. Quilès, a renowned pharmaceutical executive, brings strategic insight from her tenure at Johnson & Johnson and other industry giants. The current Transgene Board includes prominent figures like Dr. Riva and independent directors like Emmanuelle Quilès.

Transgene focuses on developing cancer immunotherapies using viral vectors. Their flagship product, TG4050, has shown clinical promise in head and neck cancer patients. The company’s portfolio also features immunotherapies targeting HPV-positive cancers (TG4001) and oncolytic viruses (BT-001, TG6050). Leveraging their myvac® platform, Transgene pioneers personalized cancer vaccines by incorporating patient-specific tumor mutations. Additionally, their invir.IO® platform creates multifunctional oncolytic viruses. For more information, visit Transgene’s website and follow their updates on social media platforms.

Read more at GlobeNewswire: Transgene nomme une experte de l’industrie pharmaceutique,